The accumulation of fat in the liver known as hepatic steatosis is a common feature of liver disease including metabolic dysfunction-associated steatotic liver disease (MASLD; previously called non-alcoholic fatty liver disease or NAFLD). The amount of fat can be quantified non-invasively by magnetic resonance imaging (MRI) proton density fat fraction (PDFF). Antaros Medical’s MRI-PDFF method includes assessment of the full 3D liver excluding bile ducts and veins. The method takes the liver volume into account to evaluate total liver fat content and assess unforeseen changes in liver physiology. These important aspects lead to an MRI-PDFF method with increased precision enabling its use in small studies with short duration to generate an early efficacy read-out for drug development.
Our methodology is scalable for large multicentre, multivendor trials keeping its high precision and quality throughout all stages of clinical research.
Read more about our precision MRI-PDFF method and experience with this method in clinical trials: Case studies – Whole liver assessment of liver PDFF and liver volume